Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Exebacase by Aurobac Therapeutics for Prosthetic Joint infections: Likelihood of Approval
Exebacase is under clinical development by Aurobac Therapeutics and currently in Phase I for Prosthetic Joint infections. According to GlobalData,...